Minnesota Opioid Deaths Fall a Third Year as Stimulants Surge

Minnesota's opioid-involved overdose deaths fell again in 2025, the third consecutive annual decline, dropping to 671 from 678 the year before, the state Department of Health reported Tuesday. The same data update shows the state's overall drug death toll moving the other way: 1,025 people died of any drug overdose in 2025, up 3 percent from 994 in 2024, with stimulants accounting for the increase.

The opioid figure is now roughly a third below the 2022 peak of 1,039 deaths. Fatal overdoses involving fentanyl, the synthetic opioid that drove the national curve upward through the pandemic, fell 6 percent between 2024 and 2025, from 602 to 564. Nonfatal hospitalizations involving opioids also edged down, from 3,685 to 3,617.

The report, Statewide Trends in Drug Overdose: 2025 Data Update, is the department's annual accounting of deaths, hospitalizations and treatment indicators, and it lands as states across the country try to read the same signal: whether the sharp national decline in overdose mortality is durable or a pause.

The stimulant side of the ledger

Minnesota's numbers split cleanly along drug class. Deaths involving methamphetamine and cocaine rose, as did hospitalizations for nonfatal stimulant overdoses, enough to outweigh the opioid decline and push the all-drug total above 1,000 for the year. For every Minnesotan who died of an overdose in 2025, another 14 were treated in a hospital and survived one, according to the department.

"We continue to see progress on preventing deadly opioid overdoses with our comprehensive public health approach involving prevention, naloxone, treatment, harm reduction and recovery services," said Minnesota Commissioner of Health Dr. Brooke Cunningham. "We must continue to advance these efforts, while applying our learnings to address the growing health impacts of increased use of stimulants like cocaine and methamphetamine."

The report offers no explanation for the divergence, and the department's own language stops short of one. What it documents is a state where the opioid measures it has spent four years building — naloxone distribution, medication access, jail-based treatment, settlement-funded peer recovery — are moving in the intended direction, while a drug class with none of those tools is not. Unlike opioid use disorder, stimulant use disorder has no FDA-approved medication, and the federal treatment infrastructure built around opioids has no stimulant equivalent.

An alert system built for exactly this

The report arrives three and a half weeks after Minnesota turned on a statewide surveillance tool designed to catch the next shift before it shows up in annual death counts. MN-OD-ALERTS, launched October 1 by the Department of Health and the state Office of Emergency Medical Services, watches EMS data for overdose spikes, clusters and unfamiliar drugs, then routes verified signals to local and Tribal public health agencies.

Seventy-six of Minnesota's 87 counties have named a contact for the system, the department said. The program was funded through a proposal from Gov. Tim Walz and appropriations from the Legislature, and it builds on the state's existing overdose surveillance work.

"Emergency medical services providers are often the first to see when something is changing in a community," said Dylan Ferguson, director of the Office of Emergency Medical Services. "By using EMS data to identify emerging overdose trends, MN-OD-ALERTS gives public health and community partners an opportunity to act earlier, before a concerning trend becomes a larger crisis."

The state described the alert system in more detail when it launched; our October 3 report covers how the county-level notifications work.

What naloxone can and cannot reach

Much of Minnesota's opioid strategy depends on a drug that has no equivalent for the substances now driving deaths upward. Naloxone reverses opioid overdoses within minutes and is now stocked for first responders and, in state-supported programs, in schools, libraries, shelters and community organizations. It does nothing for a methamphetamine or cocaine overdose, where care is supportive and there is no reversal agent at all. That asymmetry is one reason the department's recommendations for 2026 lean on naloxone access for opioids while pointing stimulant prevention toward treatment and crisis support.

The report also credits a set of programs the state has assembled since 2022: medication for opioid use disorder expanded in clinics, county jails and Tribal health programs; the Comprehensive Drug Overdose and Morbidity Prevention Act; and opioid settlement money directed to culturally specific care, peer recovery services and syringe exchange.

Whether those programs explain the three-year decline is not something the data update can establish. Overdose mortality fell nationally over the same period, and researchers continue to debate how much of the drop reflects reduced supply, changed drug use practices or expanded treatment. Minnesota's report presents the trend without attributing it.

What the department asks next

The update closes with a list aimed at local agencies and residents: strengthen local data collection, educate patients about overdose risk, carry naloxone, and route people to 988 for mental health, alcohol or drug support. It is a modest list set against a year in which the state's opioid deaths fell by seven people and its total overdose deaths rose by 31.

Minnesota's opioid curve has now bent for three straight years. The stimulant curve has not, and the state's own commissioner frames the next phase of the work around that gap rather than around the headline decline.